Weight Loss Induced by Antiobesity Medications and All‐Cause Mortality Among Patients With Knee or Hip Osteoarthritis
Authors' conclusion
In this population-based study, a slow-to-moderate, but not fast, rate of weight loss induced by antiobesity medications is associated with a lower risk of all-cause mortality in people with overweight or obesity and knee or hip OA.
Study context
- Population
- People with overweight or obesity and knee or hip osteoarthritis (OA), IQVIA Medical Research Database
- Participants
- 6,524 people
- Exposure
- Slow-to-moderate (2%-10%) or fast (≥10%) weight loss induced by antiobesity medications within one year vs weight gain or stable
- Outcome
- All-cause mortality
- Follow-up
- 5 years
Methodological detailsemulated hypothetical target trial, IQVIA Medical Research Database
- Emulated hypothetical target trial
- IQVIA Medical Research Database
Main finding
As reported in the abstract
Each group vs weight gain or stableHazard ratio (95% CI)
Slow-to-moderate weight loss
0.72(0.56–0.92)
Fast weight loss
0.99(0.67–1.44)
Observational data: associations, not effects.
Secondary outcomes
Incident hypertension, type 2 diabetes and VTE · 5 years
- Dose-response protective effects of weight loss
CVD · 5 years
- Slightly higher risk in fast weight loss vs weight gain or stable, not statistically significant
Cancer · 5 years
- No significant relation of weight loss to risk
Original publication
Weight Loss Induced by Antiobesity Medications and All‐Cause Mortality Among Patients With Knee or Hip Osteoarthritis. Arthritis Rheumatol. Published 6 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →